The National Medical Products Administration (“NMPA”), formerly the China Food and Drug Administration, has approved Omega’s Food Detective® test for self-test use in China.

Read the full RNS here

Omega has signed a contract with Abingdon Health, the UK Rapid Test Consortium (UK-RTC) lead, which sets out the terms of the supply of goods from UK-RTC members to Abingdon Health. This follows the UK Government’s initial order of one million COVID-19 lateral flow antibody tests (AbC-19™ Rapid test).

The UK-RTC contract formalises the agreement among UK-RTC members and Abingdon Health, in order for Abingdon Health to supply AbC-19™ Rapid tests to the Department of Health and Social Care (DHSC). 

Read the full RNS here

A press release was issued today by the UK Rapid Test Consortium on the UK Government’s first order for one million COVID-19 lateral flow antibody tests (AbC-19™ Rapid test).

This first order is part of the UK Government’s plans to roll-out COVID-19 surveillance studies to help build a picture of how the virus has spread across the country.

Read the full RNS here

We are pleased to announce that the self-test usability study for the UK Rapid Test Consortium’s COVID-19 lateral flow antibody test (AbC-19™ Rapid test) has concluded. The AbC-19™ Rapid test has already been CE-Marked for professional use.

Read the full RNS here

We are delighted to announce that we have CE-marked Mologic's lateral flow antibody test for COVID-19 for sale under our VISITECT^® brand.

Click here to read the full RNS

Shares in Omega Diagnostics have been on a meteoric rise this year, we sit down with CEO Colin King to discuss revolutionising COVID-19 testing and more as the business gears up for rapid growth.

Click here to read the full article

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing announces that it has signed a Memorandum of Understanding (“MOU”) with three other companies from across the UK, in conjunction with the University of Oxford to form the UK Rapid Test Consortium (“UK-RTC”) in order to jointly develop and manufacture a COVID-19 Point of Care antibody test as part of the Government’s five pillar national testing strategy for COVID-19.   Read more here: http://www.omegadiagnostics.com/Portals/0/RNS%20MOU%20on%20COVID-19%20Consortium.pdf

We are excited to announce that our portfolio of allergens has increased to 67. The allergen portfolio now includes the first screening mix to help in the diagnosis of grass allergies. Hazelnut and Almond, two important nut allergens, have been added to our common allergen list. rPen a 1 and rOle e 1, two new allergen molecules, have also been added to complement the allergy range, which aims to comprise the most prominent and clinically relevant allergens. 

Read more about our new allergen releases and their relevance at our partner's website: https://www.idsplc.com/company-news/expanding-allergy/

We are excited to announce that we have received our first purchase order for 20,000 units of its VISITECT^® CD4 Advanced Disease test from our partner company in Zimbabwe. Whilst the VISITECT^® CD4 Advanced Disease test is currently undergoing review by the UNITAID-funded Expert Review Panel for Diagnostics (ERPD), the order from Zimbabwe is not contingent upon conclusion of the ERPD process as this order will supply into B2B marketing channels, rather than NGOs.

Read the full announcement here

We are pleased to announce that we have received a purchase order from our distributor in Nigeria for 50,000 units of VISITECT^® CD4. This order is conditional upon the Nigerian Ministry of Health approving the VISITECT^® CD4 into its national HIV policy, a process which is ongoing.